Eton Pharmaceuticals/$ETON
1D1W1MYTD1Y5YMAX
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
- Ticker
- $ETON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- Deer Park, United States
- Website
- www.etonpharma.com
ETON Metrics
BasicAdvanced
$1.8B
147.31
$0.43
0.87
-
Price and volume
Market cap
$1.8B
Beta
0.87
52-week high
$66.37
52-week low
$14.27
Average daily volume
668K
Financial strength
Current ratio
1.52
Quick ratio
1.146
Long term debt to equity
43.278
Total debt to equity
62.735
Interest coverage (TTM)
4.52%
Profitability
EBITDA (TTM)
25.178
Gross margin (TTM)
61.41%
Net profit margin (TTM)
12.02%
Operating margin (TTM)
19.54%
Effective tax rate (TTM)
0.49%
Revenue per employee (TTM)
$2,400,000
Management effectiveness
Return on assets (TTM)
11.86%
Return on equity (TTM)
35.97%
Valuation
Price to earnings (TTM)
147.309
Price to revenue (TTM)
16.232
Price to book
38.29
Price to tangible book (TTM)
1,966.62
Price to free cash flow (TTM)
-6,395.821
Free cash flow yield (TTM)
-0.02%
Free cash flow per share (TTM)
-0.01
Growth
Revenue change (TTM)
81.49%
Earnings per share change (TTM)
-374.29%
3-year revenue growth (CAGR)
53.81%
3-year earnings per share growth (CAGR)
259.83%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
ETON News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.